XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisition of Bestewil (Details)
In Thousands, except Per Share data, unless otherwise specified
9 Months Ended 12 Months Ended
Sep. 30, 2010
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2012
EUR (€)
Mar. 25, 2013
Jan. 16, 2013
Mar. 31, 2009
USD ($)
Mar. 31, 2009
EUR (€)
Acquisition of Bestewil [Abstract]              
Cash consideration paid for Bestewil             € 5,000
Convertible redeemable note issued for Bestewil             2,500
Term of convertible redeemable note           36 months 36 months
Interest rate of convertible redeemable note (in hundredths)       10.00% 10.00% 5.00% 5.00%
Conversion Price (in dollars per share) $ 0.80         $ 0.50  
Percentage of acquired entity's shares used as collateral for convertible debt (in hundredths)           33.30% 33.30%
Numerator for conversion of debt   9,609          
Fair value difference between original conversion price and shares actually issued     807        
Shares to be received upon conversion (in shares) 12,011,531 19,218,450 19,218,450        
Difference between calculation of the option at original exercise price and revised exercise price     484        
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]              
Risk free interest rate (in hundredths)   0.38% 0.38%        
Expected dividends (in hundredths)   0.00% 0.00%        
Expected term   1 year 6 months 1 year 6 months        
Volatility (in hundredths)   131.92% 131.92%        
Contingent consideration cash payment from third party commence a Phase III clinical trial, maximum     € 3,000        
Percentage of net royalties receivable as contingent consideration (in hundredths)   50.00% 50.00%        
Percentage of amount received from third party for license receivable as contingent consideration (in hundredths)   25.00% 25.00%        
Discount rate of cash flows (in hundredths)   13.90% 13.90%